Evidence map›Paper›PMID 38147416›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

A novel neuroimaging signature for ADRD risk stratification in the community.

Claudia L Satizabal, Alexa S Beiser, Evan Fletcher, Sudha Seshadri, Charles DeCarli

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. A novel neuroimaging signature for ADRD risk stratification in the community.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Claudia L SatizabalGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Alexa S BeiserDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
Evan FletcherIDeA Laboratory, Department of Neurology, University of California Davis, Davis, California, USA.
Sudha SeshadriGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Charles DeCarliIDeA Laboratory, Department of Neurology, University of California Davis, Davis, California, USA.

Funding

FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 to 2024
$29.8M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI JIN, LEE-WAY · 1991 to 2020
$28.3M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEE-WAY JIN · 2021 to 2026
$25.2M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approachesU01AG058589 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOERWINKLE, ERIC A., DE JAGER, PHILIP L · 2018 to 2022
$11.1M
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and ResilienceR01AG066524 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KASHANI, AMIR H, RAMACHANDRAN, VASAN S · 2020 to 2024
$9.7M
The San Antonio Heart and Mind StudyR01AG082360 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SATIZABAL, CLAUDIA L · 2023 to 2025
$9.3M
Brain pathologies, reserve and cognition in aging and dementiaR01AG031563 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Evan Fletcher, SARAH E TOMASZEWSKI-FARIAS · 2009 to 2026
$8.9M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)RF1AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SESHADRI, SUDHA · 2018 to 2018
$6.1M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)R01AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Stephanie Anne-Carine Debette, Carole Dufouil · 2026 to 2026
$4.7M
NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01-HC-25195NIA NIH HHS P30 AG010129NIA NIH HHS P30AG010129NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072972NIA NIH HHS P30AG072972NIA NIH HHS R01 AG021028NIA NIH HHS R01AG021028NIA NIH HHS R01 AG031563NIA NIH HHS R01AG031563NIA NIH HHS R01 AG047827NIA NIH HHS R01AG047827NIA NIH HHS R01 AG049607NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG059421NIA NIH HHS R01 AG059727NIA NIH HHS R01 AG066524NIA NIH HHS R01 AG082360NIA NIH HHS R01AG082360NIA NIH HHS RF1 AG059421NIA NIH HHS RF1 AG063507NIA NIH HHS RF1 AG066524NIA NIH HHS U01 AG052409NIA NIH HHS U01 AG058589NINDS NIH HHS R01 NS017950NINDS NIH HHS U01 NS125513NINDS NIH HHS UF1 NS125513NINDS NIH HHS UF1/UH1NS125513NINDS NIH HHS UH2 NS100605
6 · The paper itself

Abstract

introductionEarly risk stratification for clinical dementia could lead to preventive therapies. We identified and validated a magnetic resonance imaging (MRI) signature for Alzheimer's disease (AD) and related dementias (ARDR).

methodsAn MRI ADRD signature was derived from cortical thickness maps in Framingham Heart Study (FHS) participants with AD dementia and matched controls. The signature was related to the risk of ADRD and cognitive function in FHS. Results were replicated in the University of California Davis Alzheimer's Disease Research Center (UCD-ADRC) cohort.

resultsParticipants in the bottom quartile of the signature had more than three times increased risk for ADRD compared to those in the upper three quartiles (P < 0.001). Greater thickness in the signature was related to better general cognition (P < 0.01) and episodic memory (P = 0.01). Results replicated in UCD-ADRC. DISCUSSION: We identified a robust neuroimaging biomarker for persons at increased risk of ADRD. Other cohorts will further test the validity of this biomarker.

Indexed as

Alzheimer DiseaseBiomarkersHumansLongitudinal StudiesNeuroimagingRisk AssessmentBiomarkersAlzheimer's diseasebiomarkerdementiaepidemiologyneuroimagingrisk prediction

Identifiers

PMID38147416
PMCPMC10984488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.